Archive
1250 articles, sorted by publication time.
The self-supervised model maintained strong identification performance across three external hospital cohorts and helped radiologists interpret scans faster and more accurately; however, the 37-minute reduction in reporting time still comes from a retrospective simulation and has not yet been shown to improve real-world patient outcomes.
Two independent laboratories confirmed that 354 of 1,320 AI-designed candidates could bind their targets, a hit rate above the reference range for typical protein design programs; but being able to “grab” a protein is still far from becoming a safe and effective drug.
The 250-patient TEMPO-1 trial is expected to begin enrollment in September, seeking accelerated approval based on tumor response rate and using overall survival to confirm long-term benefit; current efficacy signals come only from an early analysis of 21 patients.
Consano Bio’s platelet-derived multi-protein product C-1101 aims to simultaneously suppress inflammation and promote repair near damaged nerves; however, evidence of efficacy remains limited to the preclinical stage, and the ongoing 24-person trial will first address questions of safety.
Satellite Bio’s SB-101 has received clearance from the U.S. FDA to begin clinical testing. The company plans to use healthy liver cells that can be prepared in advance and cryopreserved to restore metabolic function in infants with severe early-onset urea cycle disorders; however, efficacy, safety, and whether the cells can continue functioning must still be answered by the first-in-human study.
The first patient has received a single intravenous dose, and an expansion cohort of approximately 50 people will use biomarkers including blood AAT to support a potential application; however, long-term safety and clinical benefit remain to be demonstrated.
The approximately 910-participant ALTO study will test whether simultaneous inhibition of VEGF and IL-6 can outperform aflibercept in improving vision and controlling retinopathy, while extending the dosing interval to 24 weeks for some patients.
The ALKIVIA study showed that after 52 weeks of treatment, VYVGART Hytrulo achieved a Total Improvement Score 15.4 points higher than placebo, offering a new lead for a targeted therapy for rare myositis; however, full efficacy, safety, and subtype results have yet to be released.
From premarket benchmark testing to continuous postmarket monitoring, the U.S. regulator is developing tiered rules for medical systems that generate content and may even perform tasks autonomously; the public consultation will continue through October 19.
Eyconis is using sustained-release technology to extend retinal exposure to an anti-VEGF drug, and the first patients with wet age-related macular degeneration have received treatment; whether efficacy can be maintained for six months remains to be verified in a small dose-escalation trial.
A neuroscience target proposed through genome-wide perturbation and cell-imaging models has formally entered small-molecule discovery after validation of its pathway, function, and disease phenotype; however, the target, indication, and experimental data remain undisclosed.
Using cryo-electron microscopy and biochemical experiments, researchers dissected the bacterial IS621 recombination system and found that DNA conformation and RNA pairing jointly suppress excision reactions. Rewriting the bridge RNA substantially weakened this natural barrier, but reliable editing in human cells remains some way off.